Life sciences insurance - atomic, citable facts.

Occurrence-form coverage responds to claims for incidents that occurred during the policy period regardless of when the claim is made; claims-made coverage responds only to claims first made during the policy period. For long-tail life-sciences exposures (implantable devices, pharmaceuticals), occurrence form is materially more valuable when available.

Permalink: /data#occurrence-vs-claims-made

Extended Reporting Period (ERP/tail) coverage on claims-made policies typically runs 100-300% of the expiring premium for a 5-year tail and is required when sponsor MSAs mandate insurance survival beyond the operating policy term.

Permalink: /data#erp-tail-coverage

cGMP-aligned property insurance with validation loss endorsement covers the cost to re-validate manufacturing equipment after a covered property loss; without this endorsement, a $500K equipment replacement can trigger a $2M-$5M validation re-qualification cost the standard property policy does not cover.

Permalink: /data#cgmp-property-validation

Cold-chain biologics transit requires cargo / warehouseman's legal liability coverage with temperature-excursion underwriting; standard cargo policies typically exclude temperature-related spoilage without a specific endorsement.

Permalink: /data#cargo-cold-chain-biologics

Life Sciences Liability commits to an end-of-business-day response SLA on coverage review requests.

Permalink: /data#response-sla

Time from initial broker engagement to bound, compliant program for a Texas CDMO with sponsor MSA in hand typically runs 4-8 weeks for the first program; renewals are shorter.

Permalink: /data#placement-time-to-bound

Life Sciences Liability serves life-sciences operators in all 50 US states; 16 states have hand-written practice content covering ~95% of US life-sciences industry employment: Texas, California, Massachusetts, New Jersey, New York, Florida, North Carolina, Pennsylvania, Illinois, Maryland, Washington, Connecticut, Michigan, Minnesota, Colorado, Ohio.

Permalink: /data#states-coverage

Sub-vertical practice areas: CDMOs, CROs, medical device manufacturers (Class I/II/III, FDA 510(k) and PMA), biotech and clinical-stage drug companies, compounding pharmacies (503A), 503B outsourcing facilities, GLP-1 compounders, digital health and AI healthtech startups, and clinical/diagnostic/molecular laboratories (CLIA).

Permalink: /data#sub-verticals-served

The Life Sciences Liability clause glossary contains 49 plain-English translations of insurance clauses commonly encountered in life-sciences contracts: sponsor MSAs, GPO supplier agreements, PBM credentialing packets, hospital purchase contracts, clinical trial agreements (CTAs), and 503B outsourcing agreements.

Permalink: /data#glossary-clauses

The Life Sciences Liability Q&A library contains 31 long-form answers to specific life-sciences insurance questions, each with primary-source citations (FDA, USP, HHS, HHS OIG, SEC, DOL, Texas Department of Insurance, state pharmacy boards).

Permalink: /data#qa-entries

Texas product-liability statutes provide defense-friendly protections for FDA-approved products - learned-intermediary doctrine, FDA-approval defense provisions, and statutory caps in certain product categories. Premium levels for Texas operators run roughly comparable to or modestly below Atlantic Coast clusters at similar revenue.

Permalink: /data#tx-jurisdictional-posture

The Texas Medical Records Privacy Act (HB 300, Texas Health & Safety Code Ch. 181) extends HIPAA-equivalent obligations to a broader set of entities than the federal definition; Texas life-sciences operators handling PHI face state-law cyber claims in addition to HIPAA.

Permalink: /data#tx-hb300

Certificates of Insurance (COIs) for sponsor MSAs, GPO supplier schedules, hospital purchase contracts, and PBM credentialing packets are typically required on-demand within 24-48 hours; specialty brokers maintain COI-on-demand infrastructure to meet this SLA.

Permalink: /data#ai-on-demand-coi

Life Sciences Liability does not name specific insurance carriers on the public site (Texas Department of Insurance advertising-rule compliance and agency-neutral positioning).

Permalink: /data#no-carriers-named

Life Sciences Liability is brand-led with no individual personal exposure; the platform is operated as a specialty practice and producer identity does not feature on the public site.

Permalink: /data#brand-only-positioning

Every clause translation, Q&A, state page, comparison page, and blog post on lifesciencesliability.com is hand-authored with state-, sub-vertical-, or clause-specific commentary. No templated content generation. No AI-generated content masquerading as expert analysis.

Permalink: /data#hand-written-content

MSA Indemnity Drift - field notes from sponsor MSAs reviewed in practice (qualitative, not a counted study): one-way indemnification language is the norm; most MSAs require coverages or endorsements absent from the current COI; carrier "endeavor to notify" wording rarely satisfies the 30-day notice of cancellation requirement; dedicated recall coverage is commonly missing; products towers are commonly under-sized against MSA mandates; and a growing share of MSAs tie insurance compliance to change-control or audit triggers.

Source population: pharmaceutical sponsor MSAs submitted by US-based CDMOs, CROs, and medical device manufacturers to the MSA Decoder tool 2025-2026.

Source: MSA Indemnity Drift Benchmark 2026

Permalink: /data#msa-indemnity-drift-benchmark-2026

State genetic privacy statutes create multi-million-dollar penalty exposure for molecular diagnostic labs and gene therapy operators handling genomic data: California CMIA/CCPA, Washington MHMDA (My Health My Data Act), Maryland MOPDPA (Maryland Online Privacy Data Act), Texas TDPSA (Texas Data Privacy and Security Act), Illinois GIPA (Genetic Information Privacy Act), and BIPA (Biometric Information Privacy Act).

Permalink: /data#state-genetic-privacy-statutes

Life sciences workers compensation cost is driven by the blended rate across the whole payroll, weighted by where payroll sits, not by any single class code. A biotech with 70% of payroll in office roles (clerical, NCCI 8810) and 30% in the wet lab carries a low blended rate even though the laboratory code is not cheap. Accurate payroll segregation by class code is the lever that controls cost and avoids year-end audit adjustments.

WC cost mechanics for mixed wet-lab/office/field life sciences workforces.

Source: Life Sciences Liability practice data; NCCI

Permalink: /data#wc-blended-rate-class-codes

Texas is the only US state where workers compensation is technically optional (employers may elect non-subscriber status), but a non-subscriber occupational injury program generally does not satisfy the statutory workers compensation requirement in sponsor MSAs, hospital purchase contracts, and GPO supplier schedules. Texas life sciences operators in commercial engagement with sponsors or hospitals generally maintain statutory WC regardless of the non-subscriber elective.

Texas non-subscriber status vs contractual statutory WC requirement.

Source: Texas Department of Insurance; Life Sciences Liability practice data

Permalink: /data#wc-texas-non-subscriber-msa

Umbrella and excess liability for life sciences operators is sized to the toughest contract on file, not a rule of thumb. Sponsor MSAs and hospital purchase contracts commonly require $5M-$10M total combined limits for mid-market operators and $10M-$25M+ for oncology, sterile injectable, implantable, and high-volume hospital suppliers - reached by stacking an umbrella (and excess layers) over a $1M/$2M primary general liability and products tower.

Umbrella/excess sizing against contract total-limit requirements.

Source: Life Sciences Liability practice data; IRMI

Permalink: /data#umbrella-sizing-to-contract

The load-bearing question in a life sciences excess tower is whether every layer follows form over products and completed operations. An umbrella can drop down to fill gaps; follow-form excess only adds limits over a scheduled underlying policy on its exact terms. A tower that stops following form over products at the upper layers leaves limit on paper but a coverage gap at catastrophic severity - exactly what the tower was bought to cover.

Follow-form status of excess layers over the products tower.

Source: Life Sciences Liability practice data; IRMI

Permalink: /data#umbrella-followform-products

Umbrella and excess liability extends general liability, products, auto, and employers liability - it does NOT extend directors and officers (D&O), professional liability/E&O, or cyber. Those lines carry their own limits and their own excess layers. Operators who assume the umbrella backstops everything discover the gap at a management-liability or E&O claim.

What umbrella/excess does and does not sit over.

Source: Life Sciences Liability practice data; Insurance Information Institute

Permalink: /data#umbrella-excludes-do-eo-cyber

Most pharmaceutical and medical device sponsor MSAs require $5M products and completed operations as the floor; oncology, biologics, sterile injectable, and controlled-substance manufacturing typically push the requirement to $10M and occasionally $20M.

Sponsor MSA insurance exhibit, mid-market CDMO range, US 2025-2026 underwriting cycle.

Source: Life Sciences Liability practice data, CDMO sponsor MSA reviews

Permalink: /data#cdmo-msa-products-floor

A typical Texas CDMO in the $5M-$50M revenue range pays $55,000 to $200,000 per year for a fully-compliant pharma-grade insurance program (CGL/products, professional, cyber, D&O, property/cGMP, recall).

Mid-market CDMO premium band, post-renewal 2026, Texas surplus-lines placement.

Permalink: /data#cdmo-premium-range

Sponsor MSAs increasingly require recall extension on the products liability policy sized at $1M-$5M, separate from third-party bodily injury / property damage limits.

Recall is a first-party coverage; the sponsor MSA demands it because the sponsor bears the cost of pulling product from market.

Permalink: /data#cdmo-msa-recall

Sponsor MSAs typically require survival of insurance coverage 3-7 years post-termination of the agreement; CDMOs that bind claims-made policies without extended reporting period (ERP/tail) options break this clause without realizing it.

Permalink: /data#cdmo-survival-of-coverage

30-day notice of cancellation endorsements are the most-violated insurance clause in sponsor MSAs; the standard ISO CG form provides 10-day notice for non-payment and 30 days for other reasons but requires a manuscript endorsement to satisfy most sponsor MSAs verbatim.

Permalink: /data#cdmo-msa-cancellation

The aggregate cost of an FDA Class II pharmaceutical recall typically lands in the $10M-$30M range for a mid-market manufacturer. Class III recalls (lowest risk) resolve cheaper at $1M-$5M. Class I recalls (highest risk) escalate to $50M-$600M+ given mass-tort litigation exposure.

Recall cost ranges include notification, retrieval, replacement, destruction, regulatory consulting, lost gross profit, and downstream litigation. Generalist products policies typically sublimit FDA-recall extension at $250K-$1M, insufficient for any meaningful recall event.

Source: FDA Recalls, Market Withdrawals, & Safety Alerts

Permalink: /data#pharma-recall-class-ii-cost

Typical 503B hospital purchase contract insurance schedule: $5M-$10M products liability with the hospital named as additional insured (CG 20 10 + CG 20 37), primary/non-contributory wording (CG 20 01), waiver of subrogation (CG 24 04), 30-day notice of cancellation (manuscript NOC endorsement), and FDA recall extension.

Permalink: /data#503b-hospital-schedule

Hospital purchase contract insurance schedules are enforced through automated credentialing platforms - Symplr, Reptrax, Vendormate - which lock the supplier out of the purchasing system if the certificate of insurance does not satisfy the schedule line by line.

Permalink: /data#503b-symplr-enforcement

FDA registration as a 503B outsourcing facility is a material insurance underwriting fact; loss or suspension of FDA registration is typically a notice condition in the products policy.

Permalink: /data#503b-fda-registration

Joint Commission Medication Compounding Certification (MCC) materially improves underwriting acceptance for 503B outsourcing facilities; some specialty markets require MCC for new submissions.

Permalink: /data#503b-joint-commission

Approximately 80-120 FDA-registered 503B outsourcing facilities operate in the United States at any given time. The authoritative current list is maintained by FDA at fda.gov under "Registered Outsourcing Facilities." Regional clustering: Texas (~15-20), California (~10-15), Florida (~8-12), Pennsylvania (~5-10), Indiana (~5-8), New Jersey (~5-8).

Source: FDA Registered Outsourcing Facilities

Permalink: /data#503b-fda-registered-count

A typical 503A compounding pharmacy in the $5M-$15M revenue range pays $25,000-$80,000 annually for a full program (druggist professional liability, products, CGL, cyber/HIPAA, property).

Permalink: /data#503a-premium-range

USP 797 compliance investment for a typical mid-size sterile compounder runs $50,000-$150,000 in environmental monitoring, beyond-use dating documentation, and competency training infrastructure; insurance carriers price for USP 797 compliance status at renewal.

Permalink: /data#503a-usp-797-investment

The 2023 USP 797 revision tightened beyond-use dating, environmental monitoring, and competency documentation requirements; compounders that did not update SOPs to comply face longer renewal lead times and may need to source from secondary specialty markets at materially higher premium.

Permalink: /data#503a-usp-797-2023-revision

Druggist professional liability is the primary pharmacy-error coverage for 503A compounding pharmacies; products liability covers third-party bodily injury from compounded products as a separate trigger.

Permalink: /data#503a-druggist-professional

503A compounding pharmacy staff classify under retail/store drug workers compensation codes with a compounding load, while 503B outsourcing facility production staff classify closer to drug manufacturing - making 503B workers compensation materially more expensive than 503A at comparable revenue. Misclassifying 503B production payroll under retail pharmacy codes is a year-end premium-audit exposure.

WC class-code divergence tracks the 503A vs 503B regulatory divide.

Source: Life Sciences Liability practice data; NCCI

Permalink: /data#wc-503a-vs-503b-classification

Several specialty pharmacy insurance carriers added non-FDA-approved drug exclusions to renewal endorsement schedules in 2025-2026 (often without prominent disclosure), eliminating coverage for GLP-1 compounding operators who continued production after the FDA ended shortage status.

Permalink: /data#glp1-carrier-exclusion

The March 2026 FDA enforcement wave ended shortage-list status for semaglutide and tirzepatide, materially changing the products liability underwriting posture for compounders who scaled GLP-1 operations during the 2022-2024 shortage period.

Permalink: /data#glp1-fda-enforcement-wave

For GLP-1 compounding operators, druggist professional liability (the pharmacy-error coverage) and products liability (third-party bodily injury from the compounded product) are distinct triggers; the non-FDA-approved-drug exclusion typically attaches to the products coverage, not the druggist coverage.

Permalink: /data#glp1-druggist-vs-products

After the March 2026 FDA enforcement wave ending the GLP-1 shortage list, most generalist druggist professional liability and pharmacy products liability carriers added GLP-1 exclusions at renewal. Coverage remains available through a narrower specialty market panel requiring written dose protocols, prescriber credentialing documentation, USP 797/800 compliance evidence, and adverse-event reporting workflows. Specialty market GLP-1 endorsements typically add $5K-$30K+ to base premium.

Source: FDA concerns about unapproved GLP-1 drugs

Permalink: /data#glp1-carrier-exclusions-2026

Class II/III medical device manufacturers - implantable devices, surgical equipment, neurostimulators, infusion pumps - typically carry $25M+ products liability towers, with occurrence-form coverage materially more valuable than claims-made due to 10-20 year claim tails on implantables.

Permalink: /data#medical-device-class-ii-iii-tower

GPO supplier insurance schedules - Vizient, Premier, HealthTrust - require named-additional-insured for both the GPO and member hospitals on a primary/non-contributory basis, waiver of subrogation, and 30-day notice of cancellation; the schedule is enforced through automated credentialing platforms (Symplr, Reptrax, Vendormate) which block hospital purchases when COIs do not match line by line.

Permalink: /data#medical-device-gpo-supplier

Medical Device Reporting (MDR) liability extension is required on the products policy for FDA-regulated devices; the base ISO CG form does not contemplate FDA MDR investigation defense costs.

Permalink: /data#medical-device-mdr-extension

510(k) cleared devices generally underwrite at lower products liability premium than PMA-approved devices, which generally underwrite below first-in-class or breakthrough-designation devices; the underwriting differential reflects regulatory rigor of the clearance pathway.

Permalink: /data#medical-device-510k-pma

FDA Class III implantable medical device manufacturers (pacemakers, ICDs, neurostimulators, structural heart, orthopedic implants) require occurrence-form products liability tower non-negotiably. Claims surface 10-20+ years after implant date, well outside any claims-made policy window. Typical tower $25M-$100M+ with captive insurance evaluation beginning at $250M revenue.

Source: FDA Pre-Market Approval (PMA)

Permalink: /data#class-iii-occurrence-non-negotiable

Medical device manufacturer workers compensation rates follow the operations actually performed, not the FDA product class: cleanroom and light electronics assembly price low-to-moderate, while machining, metal fabrication, and on-site ethylene oxide (EtO) sterilization raise rates. Two firms both labeled Class II device manufacturers can carry very different WC rates depending on whether they assemble sourced components or vertically integrate.

Device WC rating logic.

Source: Life Sciences Liability practice data; NCCI; OSHA

Permalink: /data#wc-device-follows-process

Pre-revenue biotech companies typically bind D&O coverage at term sheet - institutional investors require D&O before closing; first programs run $1M-$5M for seed-stage and $5M-$15M for Series A.

Permalink: /data#biotech-do-pre-revenue

Biotech IPO programs require transactional D&O (Side A DIC + B + C) typically at $25M-$100M with a 7-year discovery period for public-securities claims; pre-IPO D&O runoff (tail) for the previous program is also required.

Permalink: /data#biotech-ipo-do

Biotech IPO readiness reviews increasingly require cyber liability at $5M-$15M with explicit coverage for SEC disclosure-related cyber events under the new 4-day disclosure rule.

Permalink: /data#biotech-ipo-cyber

Sponsor-side clinical trial liability is distinct from the CRO's professional liability; biotech sponsors of clinical trials carry their own clinical trial liability policy in addition to the CRO's coverage.

Permalink: /data#biotech-clinical-trial-sponsor

Gene therapy and cell therapy clinical trial insurance requires extended reporting period (ERP) endorsements purchased at trial close-out matching FDA-mandated long-term follow-up requirements (typically 10-15 years for gene therapy). Without ERP, late-reported subject injury claims have no policy to respond - the underlying claims-made CTL form is structurally inadequate.

FDA Guidance for Industry: Long Term Follow-up After Administration of Human Gene Therapy Products (2020).

Source: FDA Long-Term Follow-Up Gene Therapy Guidance

Permalink: /data#gene-therapy-tail-coverage

VCs investing in biotech require D&O insurance as a closing condition. Term sheets routinely include a clause requiring D&O of at least $1M-$5M with Side A coverage. Pre-Series A operators bind D&O at $1M-$3M; Series A round size frequently steps up to $5M-$15M. Late-stage pre-IPO programs scale into transactional D&O territory at $25M-$100M+ Side A DIC + B + C with 7-year discovery periods.

Permalink: /data#biotech-do-term-sheet-trigger

Workers compensation for a Texas biotech at ~$5M revenue and ~30 employees (split office/wet-lab) typically runs $25,000-$60,000 annually plus $1M employers liability; a California biotech of the same size typically pays $40,000-$120,000 because of higher jurisdictional rates. BSL-3+ environments and significant chemical or radiation exposure shift these ranges upward.

Mid-market biotech WC premium band, 2026 underwriting cycle.

Source: Life Sciences Liability practice data; NCCI; WCIRB California

Permalink: /data#wc-biotech-premium-range

Sponsor-side clinical trial liability for first-in-human dosing of irreversible interventions typically runs $5M-$10M per trial; cell and gene therapy trials with FDA-mandated long-term follow-up registries require extended reporting period coverage through registry close.

Permalink: /data#cro-clinical-trial-liability

CROs handling protected health information (PHI) for clinical trials in the US must comply with HIPAA Business Associate obligations even when the trial is sponsor-funded; cyber liability towers for mid-market CROs typically run $3M-$10M.

Permalink: /data#cro-cyber-phi

Professional liability (E&O) for clinical research services typically runs $2M-$10M; sponsor indemnity obligations in master service agreements drive the upper end.

Permalink: /data#cro-professional-liability

Clinical trial insurance (clinical trial liability) sizing scales with phase: first-in-human / Phase 1 trials baseline at $5M-$10M per trial; oncology and rare disease Phase 2 cohorts typically $10M-$15M; Phase 3 with EU sites scales to $10M-$25M+ with mandatory EU Clinical Trials Regulation (CTR) compliance; investigator-sponsored trials at academic medical centers coordinate three layers (AMC self-insurance, standalone CTL, industry sponsor backstop).

Sponsor-side CTL placement standards, US 2026 underwriting cycle.

Source: Life Sciences Liability practice data, sponsor-side CTL placements

Permalink: /data#clinical-trial-insurance-phase-sizing

EU Clinical Trials Regulation (No 536/2014) requires sponsors to maintain insurance or indemnification covering trial sites and subjects in every EU member state where a study is conducted. Compliance documentation must be in place before EU site IRB / ethics committee approval; the placement is typically local-admitted policies in each member state or a master policy with country-specific endorsements.

Source: EU Clinical Trials Regulation No 536/2014

Permalink: /data#clinical-trial-insurance-eu-ctr

The sponsor pays for clinical trial liability (CTL) - the sponsor holds the IND under 21 CFR Part 312, sets the protocol, and bears the regulatory subject-protection obligation. CRO E&O sized to monitoring scope is structurally not a substitute for sponsor-side CTL. Sponsor MSAs that push CTL onto the CRO are operationally backwards.

Source: 21 CFR Part 312 - IND Application

Permalink: /data#sponsor-cto-boundary

The defining workers compensation exposure for a CRO is travel: clinical research associates and monitors spend much of their time on the road and at investigator sites, which raises claim frequency and puts the program at the intersection of WC, hired/non-owned auto, and - for ex-US trials - foreign voluntary workers compensation. Domestic statutory WC frequently does not respond to incidents abroad without a foreign voluntary endorsement.

CRO WC profile, monitoring-heavy workforce.

Source: Life Sciences Liability practice data; US DOL

Permalink: /data#wc-cro-travel-foreign-voluntary

Software-as-a-Medical-Device (SaMD) classification under FDA framework drives the insurance program - clinical decision support tools classified as Class II devices face products liability towers similar to physical medical devices; non-device software faces Tech E&O coverage instead.

Permalink: /data#samd-fda-classification

Digital health and AI healthtech startups serving enterprise customers typically carry Tech E&O sized to the largest single customer contract liability cap, plus cyber/HIPAA at $1M-$5M for PHI handling.

Permalink: /data#digital-health-tech-eo

Digital health startups raising institutional capital bind D&O at term sheet; lead investors typically require D&O before closing the round.

Permalink: /data#digital-health-do-term-sheet

Software-as-a-Medical-Device (SaMD) operators use cyber liability as the primary product-liability vehicle ($10M-$50M) because the software IS the device. The placement requires algorithm liability endorsement, training data provenance coverage, HIPAA Business Associate scope on every customer relationship, and SOC 2 Type II or HITRUST certification baseline expectation at underwriter audit.

Generic products liability is structurally inadequate for SaMD - the form does not cover algorithm errors or cyber-induced clinical decision support errors.

Source: FDA Software as a Medical Device (SaMD)

Permalink: /data#samd-cyber-primary-product-vehicle

CLIA-certified clinical laboratories carry professional liability (E&O) for lab errors, cyber/HIPAA for PHI handling, and where the lab produces lab-developed tests (LDTs), products liability with FDA enforcement-defense considerations.

Permalink: /data#clia-clinical-lab

The 2024 FDA final rule phasing in oversight of laboratory-developed tests (LDTs) as medical devices materially changed the products liability underwriting profile for clinical labs producing LDTs; products policies for LDT-producing labs require explicit MDR-extension consideration.

Permalink: /data#ldt-fda-rule

Illinois BIPA and Washington MHMDA expanded state-level biometric and health-data liability beyond HIPAA; cyber liability towers for diagnostic labs in Illinois and Washington should explicitly cover state-law claims alongside HIPAA breach response.

Permalink: /data#bipa-mhmda-cyber

Diagnostic accuracy claims (missed cancer diagnoses, false positives, sample mix-ups) are the highest claim severity category in lab insurance. Anatomic pathology generates claim severity comparable to medical professional liability. Programs should include explicit diagnostic accuracy E&O at $5M-$10M with appropriate sublimits for subspecialty categories (cytopathology, molecular pathology, dermatopathology, hematopathology).

Entity-level pathology liability sized for the lab/group business, paired with $1M/$3M individual pathologist malpractice for each physician.

Permalink: /data#pathology-liability-claim-severity

Ransomware attacks targeting clinical laboratories surged 264% in 2024-2025. Ransomware operational interruption is the single biggest claim category for CLIA-certified clinical labs - downtime on LIS, middleware, or specimen-tracking systems halts result reporting until restored. Specialty placements include explicit specimen-processing-downtime BI coverage with 4-12 hour waiting periods.

Hospital reference labs at 1M+ specimens annually commonly need $25M-$50M cyber towers sized to specimen volume, not headcount.

Permalink: /data#ransomware-clinical-labs-surge

Pathologist malpractice insurance typically runs $4,000-$15,000 per pathologist per year for $1M/$3M claims-made coverage, scaling with subspecialty (cytopathology and surgical oncology pathology run higher), state jurisdiction (Texas favorable, NY/IL/CA materially higher), and prior claims history. Anatomic pathology and surgical pathology carry materially higher premiums than clinical pathology.

Permalink: /data#pathology-malpractice-cost